@article{ca770fd421e84ec39d3db3c75027eaf9,
title = "Decreasing time to antiretroviral therapy initiation after HIV diagnosis in a clinic-based observational cohort study in four African countries",
abstract = "Introduction: World Health Organization (WHO) guidelines have shifted over time to recommend earlier initiation of antiretroviral therapy (ART) and now encourage ART initiation on the day of HIV diagnosis, if possible. However, barriers to ART access may delay initiation in resource-limited settings. We characterized temporal trends and other factors influencing the interval between HIV diagnosis and ART initiation among participants enrolled in a clinic-based cohort across four African countries. Methods: The African Cohort Study enrols adults engaged in care at 12 sites in Uganda, Kenya, Tanzania and Nigeria. Participants provide a medical history, complete a physical examination and undergo laboratory assessments every six months. Participants with recorded dates of HIV diagnosis were categorized by WHO guideline era (<2006, 2006 to 2009, 2010 to 2012, 2013 to 2015, ≥2016) at the time of diagnosis. Cox proportional hazard modelling was used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CI) for time to ART initiation. Results and discussion: From January 2013 to September 2019, a total of 2888 adults living with HIV enrolled with known diagnosis dates. Median time to ART initiation decreased from 22.0 months (interquartile range (IQR) 4.0 to 77.3) among participants diagnosed prior to 2006 to 0.5 months (IQR 0.2 to 1.8) among those diagnosed in 2016 and later. Comparing those same periods, CD4 nadir increased from a median of 166 cells/mm3 (IQR: 81 to 286) to 298 cells/mm3 (IQR: 151 to 501). In the final adjusted model, participants diagnosed in each subsequent WHO guideline era had increased rates of ART initiation compared to those diagnosed before 2006. CD4 nadir ≥500 cells/mm3 was independently associated with a lower rate of ART initiation as compared to CD4 nadir <200 cells/mm3 (HR: 0.32; 95% CI: 0.28 to 0.37). Age >50 years at diagnosis was independently associated with shorter time to ART initiation as compared to 18 to 29 years (HR: 1.38; 95% CI: 1.19 to 1.61). Conclusions: Consistent with changing guidelines, the interval between diagnosis and ART initiation has decreased over time. Still, many adults living with HIV initiated treatment with low CD4, highlighting the need to diagnose HIV earlier while improving access to immediate ART after diagnosis.",
keywords = "Africa, CD4 lymphocyte count, HIV-1, antiretroviral therapy, highly active, time-to-treatment, treatment initiation",
author = "{for the AFRICOS Study Group} and Esber, {Allahna L.} and Peter Coakley and Ake, {Julie A.} and Emmanuel Bahemana and Yakubu Adamu and Francis Kiweewa and Jonah Maswai and John Owuoth and Robb, {Merlin L.} and Polyak, {Christina S.} and Crowell, {Trevor A.} and A. Parikh and J. Hern and O. Falodun and K. Song and M. Milazzo and N. Dear and L. Francisco and S. Mankiewicz and S. Schech and A. Golway and T. Mebrahtu and E. Lee and K. Bohince and T. Hamm and K. Lombardi and M. Imbach and L. Eller and S. Peel and J. Malia and A. Kroidl and I. Kroidl and C. Geldmacher and C. Kafeero and A. Nambuya and J. Tegamanyi and H. Birungi and O. Mugagga and G. Nassali and P. Wangiri and M. Nantabo and P. Nambulondo and B. Atwijuka and A. Asiimwe and Nabanoba, {C. T.} and M. Semwogerere and R. Mwesigwa and S. Jjuuko and R. Namagembe and Williams, {T. T.}",
note = "Funding Information: This work was supported by a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD). This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Department of Defense. Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70–25. We thank the study participants, local implementing partners and hospital leadership at Kayunga District Hospital, Kericho District Hospital, AC Litein Mission Hospital, Kapkatet District Hospital, Tenwek Mission Hospital, Kapsabet District Hospital, Nandi Hills District Hospital, Kisumu West District Hospital, Mbeya Zonal Referral Hospital, Mbeya Regional Referral Hospital, Defence Headquarters Medical Center, and 68th Nigerian Army Reference Hospital. We also thank the AFRICOS Study Team: MHRP Clinical Research Directorate: A Parikh, J Hern, MHRP Data Coordination and Analysis Center: O Falodun, K Song, M Milazzo, N Dear, L Francisco, MHRP Clinical Operations Office: S Mankiewicz, S Schech, A Golway, T Mebrahtu. MHRP Department of International HIV Prevention Treatment: E Lee, K Bohince, T Hamm. MHRP International Laboratory Program: K Lombardi, M Imbach, L Eller. WRAIR HIV Diagnostics Reference Lab: S Peel, J Malia. Ludwig Maximilian University of Munich, Munich, Germany: A Kroidl, I Kroidl, C Geldmacher. Kayunga District Hospital, Kayunga, Uganda: C Kafeero, A Nambuya, J Tegamanyi, H Birungi, O Mugagga, G Nassali, P Wangiri, M Nantabo, P Nambulondo, B Atwijuka, A Asiimwe, CT Nabanoba, M Semwogerere, R Mwesigwa, S Jjuuko, R Namagembe, E Bagyendagye, A Tindikahwa, I Rwomushana, F Ssentongo, H Kibuuka, M Millard. Kericho District Hospital, Kericho, Kenya: J Kapkiai, S Wangare, R Mangesoi, P Chepkwony, L Bor, E Maera, A Kasembeli. AIC Litein Hospital, Litein, Kericho, Kenya: J Rotich, C Kipkoech, W Chepkemoi, A Rono. Kapkatet District Hospital, Kabkatet, Kericho, Kenya: Zeddy Kesi, Janet Ngeno, Edwin Langat, Keneddy Labosso, Ken Langat, Robert Kirui. Tenwek Mission Hospital, Bomet, Bomet, Kenya: L Rotich, M Mabwai, E Chelangat, J Agutu, C Tonui. Nandi Hills District Hospital, Nandi Hills, Kenya: E Changwony, M Bii, E Chumba, J Korir. Kapsabet District Hospital, Kapsabet, Nandi, Kenya: J Sugut, D Gitonga, R Ngetich, S Kiprotich. Kenya Medical Research Institute, Kisumu, Kenya: W Rehema, C Ogari, I Ouma, O Adimo, S Ogai, C Okwaro, E Maranga, J Ochola, K Obambo, V Sing'oei, L Otieno, O Nyapiedho, N Sande, E Odemba, F Wanjiru. Walter Reed Program-Tanzania, Mbeya, Tanzania: S Khamadi, E Chiweka, A Lwilla, D Mkondoo, N Somi, P Kiliba, M Nwando, G Mwaisanga, J Muhumuza. Mbeya Zonal Referral Hospital, Mbeya, Tanzania: N Mkingule, O Mwasulama, A Sanagare, P Kishimbo. National Institute of Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania: G David, F Mbwayu, J Mwamwaja, J Likiliwike, J Muhumuza, R Mcharo, N Mkingule, O Mwasulama, B Mtafya, C Lueer, A Kisinda, T Mbena, H Mfumbulwa, L Mwandumbya, P Edwin, W Olomi. Walter Reed Program-Nigeria, Abuja, Nigeria: Y Adamu, A Akintunde, AB Tiamiyu, K Afoke, S Mohammed. 68 Nigerian Army Reference Hospital, Yaba, Lagos, Nigeria: NE Harrison, UC Agbaim, OA Adegbite, Z Parker, GA Adelakun, FO Oni, RO Ndbuisi, J Elemere. Defense Headquarters Medical Center, Abuja, Nigeria: N Azuakola, TT Williams, M Ayogu, O Enas, O Enameguono, AF Odo, IC Ukaegbu, O Ugwuezumba. Defense Reference Lab, Abuja, Nigeria: SO Odeyemi, NC Okeke, L Umeji, A Rose, H Daniel, H Nwando, EI Nicholas, T Iyanda, C Okolo, VY Mene, B Dogonyaro, O Olabulo, O Akinseli, F Onukun, G Knopp. This work was supported by a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD). This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Department of Defense. Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70–25. The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense. The investigators have adhered to the policies for protection of human subjects as prescribed in AR-70. Funding Information: This work was supported by a cooperative agreement (W81XWH‐07‐2‐0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD). This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Department of Defense. Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70–25. Publisher Copyright: {\textcopyright} 2020 Henry M Foundation for the Advancement of Military Medicine. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.",
year = "2020",
month = feb,
day = "1",
doi = "10.1002/jia2.25446",
language = "English (US)",
volume = "23",
journal = "Journal of the International AIDS Society",
issn = "1758-2652",
publisher = "International AIDS Society",
number = "2",
}